Autonome, kardiovaskuläre und metabolische Wirkungen kombinierter pharmakologischer Noradrenalin- und Serotonin-Wiederaufnahme-HemmungAndreas L. Birkenfeld1.72.92.1.2.2.1011122.3.132.4.143.153.1.163.2.17590#38718614#41019624#4823.3.2021223.4.233.4.1.3.4.2.3.5.243.5.1.3.5.2.25619#363263.5.3.3.6.273.7.3.8.28631#296293.9.3.10.30408#1923.11.313.12.4.324.1.4.2.4.2.1.396#27434583#689354.2.2.36490#67237478#636384.2.3.39534#71040595#7464.3.414.3.1.463#3634.3.2.42462#3634.3.3.4344463#727454.4.46427#28647484.5.49472#373504.6.5152571#7345.535.1.5.1.1.5455565758595.1.2.605.2.61625.2.1.635.3.5.3.1.5.3.2.645.3.3.5.3.4.655.3.5.5.3.6.665.3.7.6.677.Referenzliste68 Danksagung81Publikationsliste828384 Eidestattliche Erklärung85deInhaltsverzeichnisHilfe Referenzliste [1] Rosenbaum, M.; Leibel, R. L. und Hirsch, J. (1997): Obesity, N.Engl.J.Med. 337, Seite 396-407. [2] Flegal, K. M.; Carroll, M. D.; Kuczmarski, R. J. und Johnson, C. L. (1998): Overweight and obesity in the United States: prevalence and trends, 1960-1994, Int.J.Obes.Relat Metab Disord. 22 [1], Seite 39-47. [3] Popkin, B. M. und Doak, C. M. (1998): The obesity epidemic is a worldwide phenomenon, Nutr.Rev. 56 [4 Pt 1], Seite 106-114. [4] Wadden, T. A. und Foster, G. D. (2000): Behavioral treatment of obesity, Med.Clin.North Am. 84 [2], Seite 441-61, vii. [5] Yanovski, Susan Z. und Yanovski, Jack A. (2002): Obesity, N.Engl.J.Med. 346 [8], Seite 591-602. [6] Heal, D. J.; Aspley, S.; Prow, M. R.; Jackson, H. C.; Martin, K. F. und Cheetham, S. C. (1998): Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine, Int.J.Obes.Relat Metab Disord. 22 Suppl 1S18-28; discussion S29-28. [7] Luscombe, G. P.; Slater, N. A.; Lyons, M. B.; Wynne, R. D.; Scheinbaum, M. L. und Buckett, W. R. (1990): Effect on radiolabelled-monoamine uptake in vitro of plasma taken from healthy volunteers administered the antidepressant sibutramine HCl, Psychopharmacology (Berl) 100, Seite 345-349. [8] Cheetham, S. C.; Viggers, J. A.; Slater, N. A.; Heal, D. J. und Buckett, W. R. (1993): [3H]paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: effect of administration of various antidepressant treatments, Neuropharmacology 32, Seite 737-743. [9] Cheetham, S. C.; Viggers, J. A.; Butler, S. A.; Prow, M. R. und Heal, D. J. (1996): [3H]nisoxetine--a radioligand for noradrenaline reuptake sites: correlation with inhibition of [3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments, Neuropharmacology 35, Seite 63-70. [10] Connoley, I. P.; Liu, Y. L.; Frost, I.; Reckless, I. P.; Heal, D. J. und Stock, M. J. (1999): Thermogenic effects of sibutramine and its metabolites, Br.J.Pharmacol. 126 [6], Seite 1487-1495. [11] Casado, A.; Rodriguez, V. M.; Portillo, M. P.; Macarulla, M. T.; Abecia, L. C.; Echevarria, E. und Casis, L. (2003): Sibutramine decreases body weight gain and increases energy expenditure in obese Zucker rats without changes in NPY and orexins, Nutr.Neurosci. 6 [2], Seite 103-111. [12] Hansen, D. L.; Toubro, S.; Stock, M. J.; Macdonald, I. A. und Astrup, A. (1998): Thermogenic effects of sibutramine in humans, Am.J.Clin.Nutr. 68 [6], Seite 1180-1186. [13] Walsh, K. M.; Leen, E. und Lean, M. E. (1999): The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females, Int.J.Obes.Relat Metab Disord. 23 [10], Seite 1009-1015. [14] Starling, R. D.; Liu, X. und Sullivan, D. H. (2001): Influence of sibutramine on energy expenditure in African American women, Obes.Res. 9 [4], Seite 251-256. [15] James, W. P.; Astrup, A.; Finer, N.; Hilsted, J.; Kopelman, P.; Rossner, S.; Saris, W. H. und Van Gaal, L. F. (2000): Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance, Lancet 356 [9248], Seite 2119-2125. [16] Bray, G. A.; Ryan, D. H.; Gordon, D.; Heidingsfelder, S.; Cerise, F. und Wilson, K. (1996): A double-blind randomized placebo-controlled trial of sibutramine, Obes.Res. 4 [3], Seite 263-270. [17] Cuellar, G. E.; Ruiz, A. M.; Monsalve, M. C. und Berber, A. (2000): Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population, Obes.Res. 8 [1], Seite 71-82. [18] Lundberg, J. M. (1996): Pharmacology of cotransmission in the autonomic nervous system: integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide, Pharmacol.Rev. 48, Seite 113-178. [19] Esler, M.; Jennings, G.; Lambert, G.; Meredith, I.; Horne, M. und Eisenhofer, G. (1990): Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions, Physiol Rev. 70, Seite 963-985. [20] Bachman, E. S.; Dhillon, H.; Zhang, C. Y.; Cinti, S.; Bianco, A. C.; Kobilka, B. K. und Lowell, B. B. (2002): betaAR signaling required for diet-induced thermogenesis and obesity resistance, Science 297 [5582], Seite 843-845. [21] Ordway, G. A.; Stockmeier, C. A.; Cason, G. W. und Klimek, V. (1997): Pharmacology and distribution of norepinephrine transporters in the human locus coeruleus and raphe nuclei, J.Neurosci. 17, Seite 1710-1719. [22] Olivier, B.; Soudijn, W. und van, Wijngaarden, I (2000): Serotonin, dopamine and norepinephrine transporters in the central nervous system and their inhibitors, Prog.Drug Res.2000.;54.:59.-119. 54, Seite 59-119. [23] Risch, S. C. und Nemeroff, C. B. (1992): Neurochemical alterations of serotonergic neuronal systems in depression, J.Clin.Psychiatry 53 Suppl, Seite 3-7. [24] Barnes, N. M. und Sharp, T. (1999): A review of central 5-HT receptors and their function, Neuropharmacology 38, Seite 1083-1152. [25] Ramamoorthy, S.; Bauman, A. L.; Moore, K. R.; Han, H.; Yang-Feng, T.; Chang, A. S.; Ganapathy, V. und Blakely, R. D. (1993): Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization, Proc.Natl.Acad.Sci.U.S.A 90, Seite 2542-2546. [26] Takata, T. S.; Wasmund, S. L.; Smith, M. L.; Li, J. M.; Joglar, J. A.; Banks, K.; Kowal, R. C.; Page, R. L. und Hamdan, M. H. (2002): Serotonin reuptake inhibitor (Paxil) does not prevent the vasovagal reaction associated with carotid sinus massage and/or lower body negative pressure in healthy volunteers, Circulation 106 [12], Seite 1500-1504. [27] Glassman, A. H.; O'Connor, C. M.; Califf, R. M.; Swedberg, K.; Schwartz, P.; Bigger, J. T., Jr.; Krishnan, K. R.; van Zyl, L. T.; Swenson, J. R.; Finkel, M. S.; Landau, C.; Shapiro, P. A.; Pepine, C. J.; Mardekian, J.; Harrison, W. M.; Barton, D. und Mclvor, M. (2002): Sertraline treatment of major depression in patients with acute MI or unstable angina, JAMA 288 [6], Seite 701-709. [28] Andrews, C. und Pinner, G. (1998): Postural hypotension induced by paroxetine, BMJ 316 [7131], Seite 595. [29] Schroeder, Christoph; Tank, Jens; Boschmann, Michael; Diedrich, Andre; Sharma, Arya M.; Biaggioni, Italo; Luft, Friedrich C. und Jordan, Jens (2002): Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance, Circulation 105 [3], Seite 347-353. [30] Tank, J.; Schroeder, C.; Diedrich, A.; Szczech, E.; Haertter, S.; Sharma, A. M.; Luft, F. C. und Jordan, J. (2003): Selective impairment in sympathetic vasomotor control with norepinephrine transporter inhibition, Circulation 107 [23], Seite 2949-2954. [31] Pacholczyk, T.; Blakely, R. D. und Amara, S. G. (1991): Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter, Nature 350, Seite 350-354. [32] Ross, R. J.; Zavadil, A. P., III; Calil, H. M.; Linnoila, M.; Kitanaka, I.; Blombery, P.; Kopin, I. J. und Potter, W. Z. (1983): Effects of desmethylimipramine on plasma norepinephrine, pulse, and blood pressure, Clin.Pharmacol.Ther. 33, Seite 429-437. [33] Esler, M. D.; Wallin, G.; Dorward, P. K.; Eisenhofer, G.; Westerman, R.; Meredith, I.; Lambert, G.; Cox, H. S. und Jennings, G. (1991): Effects of desipramine on sympathetic nerve firing and norepinephrine spillover to plasma in humans, Am.J.Physiol 260 [4 Pt 2], Seite R817-R823. [34] Eisenhofer, G.; Saigusa, T.; Esler, M. D.; Cox, H. S.; Angus, J. A. und Dorward, P. K. (1991): Central sympathoinhibition and peripheral neuronal uptake blockade after desipramine in rabbits, Am.J.Physiol 260 [4 Pt 2], Seite R824-R832. [35] Kim, S. H.; Lee, Y. M.; Jee, S. H. und Nam, C. M. (2003): Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials, Obes.Res. 11 [9], Seite 1116-1123. [36] Hirsch, J.; Mackintosh, R. M. und Aronne, L. J. (2000): The effects of drugs used to treat obesity on the autonomic nervous system, Obes.Res. 8 [3], Seite 227-233. [37] Grassi, G.; Seravalle, G.; Cattaneo, B. M.; Bolla, G. B.; Lanfranchi, A.; Colombo, M.; Giannattasio, C.; Brunani, A.; Cavagnini, F. und Mancia, G. (1995): Sympathetic activation in obese normotensive subjects, Hypertension 25, Seite 560-563. [38] Mark, A. L.; Correia, M.; Morgan, D. A.; Shaffer, R. A. und Haynes, W. G. (1999): State-of-the-art-lecture: Obesity-induced hypertension: new concepts from the emerging biology of obesity, Hypertension 33 [1 Pt 2], Seite 537-541. [39] Rumantir, M. S.; Vaz, M.; Jennings, G. L.; Collier, G.; Kaye, D. M.; Seals, D. R.; Wiesner, G. H.; Brunner-La Rocca, H. P. und Esler, M. D. (1999): Neural mechanisms in human obesity-related hypertension, J.Hypertens. 17 [8], Seite 1125-1133. [40] Engeli, S. und Sharma, A. M. (2001): The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension, J.Mol.Med. 79 [1], Seite 21-29. [41] Gundlah, C.; Martin, K. F.; Heal, D. J. und Auerbach, S. B. (1997): In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor, J.Pharmacol.Exp.Ther. 283 [2], Seite 581-591. [42] Buckett, W. R.; Thomas, P. C. und Luscombe, G. P. (1988): The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation, Prog.Neuropsychopharmacol.Biol.Psychiatry 12 [5], Seite 575-584. [43] Cheetham, S. C.; Kettle, C. J.; Martin, K. F. und Heal, D. J. (1995): D1 receptor binding in rat striatum: modification by various D1 and D2 antagonists, but not by sibutramine hydrochloride, antidepressants or treatments which enhance central dopaminergic function, J.Neural Transm.Gen.Sect. 102, Seite 35-46. [44] Glick, S. D.; Haskew, R. E.; Maisonneuve, I. M.; Carlson, J. N. und Jerussi, T. P. (2000): Enantioselective behavioral effects of sibutramine metabolites, Eur.J.Pharmacol. 397 [1], Seite 93-102. [45] Luque, C. A. und Rey, J. A. (1999): Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity, Ann.Pharmacother. 33 [9], Seite 968-978. [46] Hind, I. D.; Mangham, J. E.; Ghani, S. P.; Haddock, R. E.; Garratt, C. J. und Jones, R. W. (1999): Sibutramine pharmacokinetics in young and elderly healthy subjects, Eur.J.Clin.Pharmacol. 54 [11], Seite 847-849. [47] Bristow, M. R. (2000): beta-adrenergic receptor blockade in chronic heart failure, Circulation 101 [5], Seite 558-569. [48] Otton, S. V.; Crewe, H. K.; Lennard, M. S.; Tucker, G. T. und Woods, H. F. (1988): Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes, J.Pharmacol.Exp.Ther. 247, Seite 242-247. [49] Kim, M.; Shen, D. D.; Eddy, A. C.; Nelson, W. L. und Roskos, L. K. (1993): Inhibition of the enantioselective oxidative metabolism of metoprolol by verapamil in human liver microsomes, Drug Metab Dispos. 21, Seite 309-317. [50] Lennard, M. S.; Tucker, G. T.; Silas, J. H.; Freestone, S.; Ramsay, L. E. und Woods, H. F. (1983): Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers, Clin.Pharmacol.Ther. 34, Seite 732-737. [51] Cruickshank, J. M.; Neil-Dwyer, G.; Cameron, M. M. und McAinsh, J. (1980): beta-Adrenoreceptor-blocking agents and the blood-brain barrier, Clin.Sci.(Lond) 59 Suppl 6, Seite 453s-455s. [52] Jordo, L.; Attman, P. O.; Aurell, M.; Johansson, L.; Johnsson, G. und Regardh, C. G. (1980): Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function, Clin.Pharmacokinet. 5, Seite 169-180. [53] Hoffmann, K. J.; Regardh, C. G.; Aurell, M.; Ervik, M. und Jordo, L. (1980): The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites, Clin.Pharmacokinet. 5, Seite 181-191. [54] Sherwood, A.; Allen, M. T.; Fahrenberg, J.; Kelsey, R. M.; Lovallo, W. R. und van Doornen, L. J. (1990): Methodological guidelines for impedance cardiography, Psychophysiology 27 [1], Seite 1-23. [55] Bernstein, D. P. (1986): A new stroke volume equation for thoracic electrical bioimpedance: theory and rationale, Crit Care Med. 14 [10], Seite 904-909. [56] Kollai, M. und Koizumi, K. (1981): Cardiovascular reflexes and interrelationships between sympathetic and parasympathetic activity, J.Auton.Nerv.Syst. 4 [2], Seite 135-148. [57] Ewing, D. J.; Borsey, D. Q.; Bellavere, F. und Clarke, B. F. (1981): Cardiac autonomic neuropathy in diabetes: comparison of measures of R-R interval variation, Diabetologia 21 [1], Seite 18-24. [58] Mosqueda-Garcia, R. (1995): Evaluation of Autonomic Failure In: Disorders of the Autonomic Nervous System. Robertson D, Biaggioni I, editors I[3], 25-54. 1995. Nashville, Harwood Academic Publishers. The Autonomic Nervous System. Burnstock, G. [59] Palkovits, M. und Zaborszky, L. (1977): Neuroanatomy of central cardiovascular control. Nucleus tractus solitarii: afferent and efferent neuronal connections in relation to the baroreceptor reflex arc, Prog.Brain Res. 47, Seite 9-34. [60] Levin, A. B. (1966): A simple test of cardiac function based upon the heart rate changes induced by the Valsalva maneuver, Am.J.Cardiol. 18 [1], Seite 90-99. [61] Lind, AR; Taylor, SH; Humphreys, PW; Kennelly, BM und Donald, KW (1964): The circulatiory effects of sustained voluntary muscle contraction., Clin.Sci. 27, Seite 229-244. [62] Freyschuss, U. (1970): Cardiovascular adjustment to somatomotor activation. The elicitation of increments in heart rate, aortic pressure and venomotor tone with the initiation of muscle contraction, Acta Physiol Scand.Suppl 342, Seite 1-63. [63] Vissing, J.; MacLean, D. A.; Vissing, S. F.; Sander, M.; Saltin, B. und Haller, R. G. (2001): The exercise metaboreflex is maintained in the absence of muscle acidosis: insights from muscle microdialysis in humans with McArdle's disease, J.Physiol 537 [Pt 2], Seite 641-649. [64] Goldstein, D. S.; Polinsky, R. J.; Garty, M.; Robertson, D.; Brown, R. T.; Biaggioni, I.; Stull, R. und Kopin, I. J. (1989): Patterns of plasma levels of catechols in neurogenic orthostatic hypotension, Ann.Neurol. 26 [4], Seite 558-563. [65] (1996): Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology, Circulation 93 [5], Seite 1043-1065. [66] Omboni, S.; Parati, G.; Di Rienzo, M.; Wieling, W. und Mancia, G. (1996): Blood pressure and heart rate variability in autonomic disorders: a critical review, Clin.Auton.Res. 6 [3], Seite 171-182. [67] Akselrod, S.; Gordon, D.; Ubel, F. A.; Shannon, D. C.; Berger, A. C. und Cohen, R. J. (1981): Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control, Science 213 [4504], Seite 220-222. [68] Mayer, S. (1876): Über spontane Blutdruckschwankungen, Sber.Akad.Wiss.Wien 74, Seite 281. [69] Bertinieri, G.; Di Rienzo, M.; Cavallazzi, A.; Ferrari, A. U.; Pedotti, A. und Mancia, G. (1985): A new approach to analysis of the arterial baroreflex, J.Hypertens.Suppl 3 Suppl 3, Seite S79-S81. [70] Tank, J.; Jordan, J.; Diedrich, A.; Stoffels, M.; Franke, G.; Faulhaber, H. D.; Luft, F. C. und Busjahn, A. (2001): Genetic influences on baroreflex function in normal twins, Hypertension 37 [3], Seite 907-910. [71] Pagani, M.; Lombardi, F.; Guzzetti, S.; Rimoldi, O.; Furlan, R.; Pizzinelli, P.; Sandrone, G.; Malfatto, G.; Dell'Orto, S.; Piccaluga, E. und . (1986): Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog, Circ.Res. 59 [2], Seite 178-193. [72] Ferrannini, E. (1988): The theoretical bases of indirect calorimetry: a review, Metabolism 37 [3], Seite 287-301. [73] Guyton, AC and Hall, J. E. (2000): Protein Metabolism In: Textbook of medical physiology. Guyton A, Hall JE, editors [10], 791-796.2000. Pilapelphia, W.B. Saunders. [74] Shannon, J. R.; Flattem, N. L.; Jordan, J.; Jacob, G.; Black, B. K.; Biaggioni, I.; Blakely, R. D. und Robertson, D. (2000): Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency, N.Engl.J.Med. 342 [8], Seite 541-549. [75] McMahon, F. G.; Fujioka, K.; Singh, B. N.; Mendel, C. M.; Rowe, E.; Rolston, K.; Johnson, F. und Mooradian, A. D. (2000): Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial, Arch.Intern.Med. 160 [14], Seite 2185-2191. [76] Heal, D. J.; Prow, M. R. und Buckett, W. R. (1991): Effects of antidepressant drugs and electroconvulsive shock on pre- and postsynaptic alpha 2-adrenoceptor function in the brain: rapid down-regulation by sibutramine hydrochloride, Psychopharmacology (Berl) 103 [2], Seite 251-257. [77] Birkenfeld, AL; Schroeder, C; Tank, J; Luft, F. C. und Jordan, J. (2003): Cardiovascular effects of combined norepinephrine and serotonin transporter inhibition vs sole norepinephrine transporter inhibition. Abstract , Clincal Autonomic Research 13 [2], Seite 133-133. [78] Kahan, T.; Hjemdahl, P. und Dahlof, C. (1984): Relationship between the overflow of endogenous and radiolabelled noradrenaline from canine blood perfused gracilis muscle, Acta Physiol Scand. 122 [4], Seite 571-582. [79] Goldstein, D. S.; Brush, J.-E. Jr; Eisenhofer, G.; Stull, R. und Esler, M. (1988): In vivo measurement of neuronal uptake of norepinephrine in the human heart, Circulation 78 [1], Seite 41-48. [80] McLeod, J. G. und Tuck, R. R. (1987): Disorders of the autonomic nervous system: Part 2. Investigation and treatment, Ann.Neurol. 21 [6], Seite 519-529. [81] Woolard, Jeanette; Bennett, Terence; Dunn, William R.; Heal, David J.; Aspley, Susan und Gardiner, Sheila M. (2004): Acute Cardiovascular Effects of Sibutramine in Conscious Rats, Journal of Pharmacology And Experimental Therapeutics 308 [3], Seite 1102-1110. URL: http://jpet.aspetjournals.org/cgi/content/abstract/308/3/1102 [82] Preiss, G. und Polosa, C. (1974): Patterns of sympathetic neuron activity associated with Mayer waves, Am.J.Physiol 226 [3], Seite 724-730. [83] Landsberg, L. und Krieger, D. R. (1989): Obesity, metabolism, and the sympathetic nervous system, Am.J.Hypertens. 2, Seite 125S-132S. [84] Masuo, K.; Mikami, H.; Ogihara, T. und Tuck, M. L. (2001): Familial obesity, sympathetic activation and blood pressure level, Blood Press 10 [4], Seite 199-204. [85] Hansen, D. L.; Toubro, S.; Stock, M. J.; Macdonald, I. A. und Astrup, A. (1999): The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction, Int.J.Obes.Relat Metab Disord. 23 [10], Seite 1016-1024. [86] van Baak, M. A.; van Mil, E.; Astrup, A. V.; Finer, N.; Van Gaal, L. F.; Hilsted, J.; Kopelman, P. G.; Rossner, S.; James, W. P. und Saris, W. H. (2003): Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial), Am.J.Clin.Nutr. 78 [2], Seite 209-214. [87] Sramek, J. J.; Leibowitz, M. T.; Weinstein, S. P.; Rowe, E. D.; Mendel, C. M.; Levy, B.; McMahon, F. G.; Mullican, W. S.; Toth, P. D. und Cutler, N. R. (2002): Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial, J.Hum.Hypertens. 16 [1], Seite 13-19. [88] Esler, M.; Jackman, G.; Leonard, P.; Skews, H.; Bobik, A. und Jennings, G. (1981): Effect of propranolol on noradrenaline kinetics in patients with essential hypertension, Br.J.Clin.Pharmacol. 12, Seite 375-380. [89] Tank, J.; Diedrich, A.; Schroeder, C.; Stoffels, M.; Franke, G.; Sharma, A. M.; Luft, F. C. und Jordan, J. (2001): Limited effect of systemic beta-blockade on sympathetic outflow, Hypertension 38 [6], Seite 1377-1381. [90] Jordan, J. und Sharma, A. M. (2003): Potential for sibutramine-yohimbine interaction?, Lancet 361 [9371], Seite 1826. [91] Sharma, A. M.; Pischon, T.; Hardt, S.; Kunz, I. und Luft, F. C. (2001): Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis, Hypertension 37 [2], Seite 250-254. [92] Esler, M.; Hastings, J.; Lambert, G.; Kaye, D.; Jennings, G. und Seals, D. R. (2002): The influence of aging on the human sympathetic nervous system and brain norepinephrine turnover, Am.J.Physiol Regul.Integr.Comp Physiol 282 [3], Seite R909-R916. [93] Hinojosa-Laborde, C.; Chapa, I.; Lange, D. und Haywood, J. R. (1999): Gender differences in sympathetic nervous system regulation, Clin.Exp.Pharmacol.Physiol 26 [2], Seite 122-126. [94] Manolio, T. A.; Fishel, S. C.; Beattie, C.; Torres, J.; Christopherson, R.; Merritt, W. T. und Whelton, P. K. (1988): Evaluation of the Dinamap continuous blood pressure monitor, Am.J.Hypertens. 1, Seite 161S-167S. [95] Petersen, M. E.; Williams, T. R. und Sutton, R. (1995): A comparison of non-invasive continuous finger blood pressure measurement (Finapres) with intra-arterial pressure during prolonged head-up tilt, Eur.Heart J. 16, Seite 1641-1654. [96] Jagomagi, K.; Raamat, R. und Talts, J. (2001): Effect of altering vasoactivity on the measurement of finger blood pressure, Blood Press Monit. 6 [1], Seite 33-40. [97] Jellema, W. T.; Imholz, B. P.; van Goudoever, J.; Wesseling, K. H. und van Lieshout, J. J. (1996): Finger arterial versus intrabrachial pressure and continuous cardiac output during head-up tilt testing in healthy subjects, Clin.Sci.(Lond) 91, Seite 193-200. [98] Esler, M.; Jennings, G.; Korner, P.; Willett, I.; Dudley, F.; Hasking, G.; Anderson, W. und Lambert, G. (1988): Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover, Hypertension 11 [1], Seite 3-20. [99] Ninomiya, I.; Irisawa, A. und Nisimaru, N. (1973): Nonuniformity of sympathetic nerve activity to the skin and kidney, Am.J.Physiol 224 [2], Seite 256-264. [100] Leimbach, W.-N. Jr; Wallin, B. G.; Victor, R. G.; Aylward, P. E.; Sundlof, G. und Mark, A. L. (1986): Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure, Circulation 73 [5], Seite 913-919. [101] Anderson, E. A.; Sinkey, C. A.; Lawton, W. J. und Mark, A. L. (1989): Elevated sympathetic nerve activity in borderline hypertensive humans. Evidence from direct intraneural recordings, Hypertension 14 [2], Seite 177-183. [102] Carruthers, M.; Conway, N.; Somerville, W.; Taggart, P. und Bates, D. (1970): Validity of plasma-catecholamine estimations, Lancet 1 [7663], Seite 62-67. [103] Dimsdale, J. E. und Ziegler, M. G. (1991): What do plasma and urinary measures of catecholamines tell us about human response to stressors?, Circulation 83 [4 Suppl], Seite II36-II42. [104] Pickett, B. R. und Buell, J. C. (1992): Validity of cardiac output measurement by computer-averaged impedance cardiography, and comparison with simultaneous thermodilution determinations, Am.J.Cardiol. 69 [16], Seite 1354-1358. [105] Pickett, B. R. und Buell, J. C. (1992): Validity of cardiac output measurement by computer-averaged impedance cardiography, and comparison with simultaneous thermodilution determinations, Am.J.Cardiol. 69, Seite 1354-1358. [106] Ebert, T. J.; Eckberg, D. L.; Vetrovec, G. M. und Cowley, M. J. (1984): Impedance cardiograms reliably estimate beat-by-beat changes of left ventricular stroke volume in humans, Cardiovasc.Res. 18, Seite 354-360. [107] Di Girolamo, E.; Di Iorio, C.; Leonzio, L.; Sabatini, P. und Barsotti, A. (1999): Usefulness of a tilt training program for the prevention of refractory neurocardiogenic syncope in adolescents: A controlled study, Circulation 100 [17], Seite 1798-1801. [108] Ainslie, P.; Reilly, T. und Westerterp, K. (2003): Estimating human energy expenditure: a review of techniques with particular reference to doubly labelled water, Sports Med.2003.;33.(9.):683.-98. 33, Seite 683-698. [109] Hayano, J.; Sakakibara, Y.; Yamada, A.; Yamada, M.; Mukai, S.; Fujinami, T.; Yokoyama, K.; Watanabe, Y. und Takata, K. (1991): Accuracy of assessment of cardiac vagal tone by heart rate variability in normal subjects, Am.J.Cardiol. 67, Seite 199-204. [110] Cohen, M. A. und Taylor, J. A. (2002): Short-term cardiovascular oscillations in man: measuring and modelling the physiologies, J.Physiol 542 [Pt 3], Seite 669-683. [111] Eckberg, D. L. (1998): Sympathovagal balance: a critical appraisal. Reply, Circulation 98, Seite 2643-2644.